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333* Characteristics of visual function in adults with cystic ﬁbrosis
K.S. Evans1, C. Purslow1, R.V. North1, R.I. Ketchell2. 1School of Optometry &
Vision Sciences, Cardiff University, Cardiff, United Kingdom; 2All Wales Adult
Cystic Fibrosis Centre, Llandough Hospital, Cardiff, United Kingdom
Objectives: Ocular abnormalities have been observed in CF subjects including:
impaired dark adaptation, contrast sensitivity and colour vision. Previous studies
are small and have included confounding factors. This study aims to compare visual
function (VF) in CF subjects of known vitamin A and diabetic status, with healthy
controls.
Methods: Distance and near visual acuity (DVA, NVA), contrast sensitivity (CS),
colour vision (CV), dark adaptation (DA) and retinal photographs were recorded
from 28 CF subjects (19m, 9f; 27±7.4 years) and matched controls.
Results: CF subjects displayed signiﬁcantly reduced NVA (p< 0.05), CS
(p< 0.005), DA (p< 0.005) and CV (p< 0.01) compared to controls (t-test). Consid-
ering CF subjects, diabetes (n =11, 45% with diabetic retinopathy) had no signiﬁcant
effect on VF apart from DA (p< 0.05). Low vitamin A level (<1.10 mmol/L, n = 12)
had no signiﬁcant effect on VF. There was no signiﬁcant correlation of vitamin A
status and DA thresholds (r = −0.282) although one deﬁcient subject exhibited a
complete absence of the normal rod retinal photoreceptor response. Generally, VF
in DF508 homozygotes (n = 12) appeared to be reduced compared to heterozygotes
(n = 11) although this failed to reach signiﬁcance.
Conclusions: VF is adversely affected in CF. CFTR has been detected in a
layer of the retina known as the retinal pigment epithelium (RPE). Abnormal ion
transport across the RPE is likely to impair normal VF. These results support the
hypothesis that abnormal VF is a primary manifestation of CF which is exacerbated
by genotype, vitamin A insufﬁciency and CFRD. These ﬁndings highlight the
importance of regular eye examinations and education of eye care professionals
to the ocular associations of CF.
334* Autonomic neuropathy in cystic ﬁbrosis
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Cardiovascular autonomic neuropathy (CAN) is an important form of diabetic
autonomic neuropathy causing increased morbidity and mortality. The prevalence
of such diabetic complications in cystic ﬁbrosis (CF) is likely to rise with increasing
survival. The aim of this study was to assess the prevalence of CAN in our adult
CF population.
Methods: Heart rate variability (HRV) testing during slow respiration, a valsalva
manouvere and in standing from supine (measures of parasympathetic function)
were performed using ECG monitoring as recommended by American Diabetic
Association. Early and deﬁnite involvement of CAN was deﬁned as 1 and 2 or
more positive tests respectively. Blood pressure (BP) response to standing from
supine and isometric exercise were also measured to assess sympathetic function.
Vitamin E levels and complications of CF were recorded.
Results: 43 patients were screened, 27 had CF related diabetes (CFRD) (mean age
28), 5 had impaired glucose tolerance (GT) (mean age 28), and 11 had normal GT
(mean age 30).
Of the 43, 25 (58%) had deﬁnite involvement, 13 (30%) had an early involvement
and 5 (11%) had no evidence of CAN. There was no signiﬁcant response of BP to
standing in any group whilst isometric exercise was not found to be reproducible.
Conclusions: Although CAN appears prevalent in CFRD, it was also evident in our
non-diabetic CF group. Vitamin E deﬁciency and chronic liver disease may explain
such ﬁndings but this was not evident in our population. Autonomic neuropathy in
CF warrants further investigation.
No. of +ve tests according to diabetic status
No.of +ve tests CFRD (27) CF impaired GT (5) CF Non-Dm (11)
0 (Normal) 3 (11%) 2 (40%) 0
1 (Early involvement) 6 (22%) 1 (20%) 6 (54%)
2 (Deﬁnite) 18 (67%) 2 (40%) 5 (46%)
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Introduction: Thyroid function has not been adequately assessed longitudinally in
cystic ﬁbrosis patients as yet.
Aim of the study: To investigate thyroid function in newly diagnosed cystic
ﬁbrosis patients, and to follow the natural course of possible thyroid alterations
with pancreatic enzyme substitution treatment.
Patients and methods: Fourteen newly diagnosed patients (7male/ 7female, mean
age 5 months [range 1−19 months]), all with pancreatic insufﬁciency, were evaluated
regarding their thyroid function at diagnosis of cystic ﬁbrosis and for 6 months
ensuing onset of pancreatic enzyme substitution therapy.
Results: All infants displayed normal TSH values in neonatal screening. Eleven
out of 14 (80%) had hyperthyrotropinemia, while all had normal freeT4 and
freeT3 values upon initiation of enzyme substitution therapy. Within the ﬁrst
month of therapy, TSH values were normalized in 60% of the cohort while
the rest demonstrated a persistent TSH elevation for a longer period. At re-
evaluation, after 3−6 months, 70% of the patients had normal TSH values while on
pancreatic enzyme substitution even though they received no thyroxine treatment.
The correction of hyperthyrotropinemia might be partly associated with restitution
of defective absorption of various minerals.
Conclusions: Mild TSH elevation, reminiscent of subclinical hypothyroidism, is
a frequent ﬁnding in newly diagnosed cystic ﬁbrosis patients with pancreatic
insufﬁciency during infancy. TSH elevation resolves in the majority of cases
3−6 months after initiation of enzyme substitution therapy.
336 Assessment of bone mineralisation in cystic ﬁbrosis
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CF patients may develop low bone mineral density (BMD), leading to an increase in
bone fragility and susceptibility to fracture. In 2007 the UK CF Trust published its
consensus guidelines on Bone Mineralisation in CF. We have audited our current
practice against these guidelines. The notes of 47 adult CF patients [24 female,
mean (range) age 30 (17−57), mean FEV1 65% predicted (20–115%), mean
BMI 22.7(16.9−32.5)] receiving full or shared care at our centre were reviewed.
35 patients (74%) were pancreatic insufﬁcient, 2 were post transplant and 7 were
on long-term (>3 months) oral corticosteroids.
14 patients (30%) had ever had a bone densitometry (DEXA) scan, of whom 11
had a scan in the last 3 years. 7 (50%) had their calcium and vitamin D levels
measured in the previous 12 months. None of the patients had their CXR routinely
reviewed for vertebral fractures.
Of those who had a DEXA scan, 3 were normal (Z score >−1), 3 met the criteria
for CF-related low BMD (Z score of <−2) and 4 had a signiﬁcantly reduced BMD
(Z score −1.5-−2). 1 patient had a Z score of −1.4. The results of the 3 remaining
scans were not available. Of those with CF-related low BMD the mean (range)
of FEV1 was 36% predicted (20−54%) and the mean (range) BMI was 21.4
(19.8−24.3). Amongst these patients, 1 was on bisphosphonate treatment whilst
completing a prolonged course of steroids.
This audit demonstrates that many of our patients are not having their bone
mineralisation status assessed. Of those assessed, 21% had CF-related low BMD.
Although the numbers in this patient group are small, recognition that CF-related
low BMD may occur in those with above average clinical status, (as deﬁned
by FEV1 and BMI) has re-emphasised the importance of incorporating bone
mineralisation measurement into our centre’s annual review for all patients.
